AssociatiNG Bevacizumab bEmarituzumab for GynecoLogIcal CAncer
Status:
NOT_YET_RECRUITING
Trial end date:
2030-10-15
Target enrollment:
Participant gender:
Summary
The aim of this study is to determine the Maximum Tolerated Dose (MTD) and Recommended Phase 2 Dose (RP2D) of bemarituzimab given in combination with a fixed dose of bevacizumab and to assess the clinical activity of the proposed combination bemarituzumab and bevacizumab in 3 parallel and independent cohorts of gynecological cancer (endometrium, ovary and cervix).